Cargando…
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment
BACKGROUND: It was shown that immunocompromised patients have significantly reduced immunologic responses to COVID-19 vaccines. The immunogenicity of COVID-19 vaccine/infection in patients with solid tumors is reduced. We evaluated the immunologic response to COVID-19 and/or the BNT162b2 mRNA COVID-...
Autores principales: | Grinshpun, A., Rottenberg, Y., Ben-Dov, I.Z., Djian, E., Wolf, D.G., Kadouri, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469519/ https://www.ncbi.nlm.nih.gov/pubmed/34634634 http://dx.doi.org/10.1016/j.esmoop.2021.100283 |
Ejemplares similares
-
Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022) -
Breast Cancer with Low Recurrence Score on Oncotype DX(©): Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
por: Zarbiv, Yonaton, et al.
Publicado: (2022) -
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
por: Amirthalingam, Gayatri, et al.
Publicado: (2021) -
Serological response to vaccination in post-acute sequelae of COVID
por: Joung, Sandy, et al.
Publicado: (2023) -
Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination
por: McGee, Christopher, et al.
Publicado: (2022)